Funding to accelerate the iteration of the proprietary AI-driven ExCEED platform and advance global clinical development of differentiated pipelines, including a second-generation Menin inhibitor and a novel ophthalmic therapy. CHENGDU, China, Aug. 12, 2026 /PRNewswire/ -- Beyang Therapeutics Co., Ltd. ("Beyang"), an AI-driven innovative drug R&D company dedicated to building a "DreamWorks" for innovative drug discovery, today announced the successful closing of an oversubscribed Series A financing round, raising nearly $30 million. The round was co-led by Legend Capital and Shanghai HeREAD FULL ARTICLE